Pharmacologic treatments for covid-19 patients
Below you can access forest plots for all the treatment comparisons as well as the general characteristics of each trial with risk of bias assessment.
Analyses are updated every Friday.
Of note, the search “display new or updated results” may identify comparisons not tagged as ‘updated’ when a trial related to this comparison has been identified or updated and is reported in the table but is not yet included in the analysis.
More details about outcomes and Disease severity
Specific search
Display only new or updated results
Your research: comparisons updated with new studies
Create and download your forest plots with the most up-to-date data here Forest plots
Treatment comparisons
Access the forest plots for the 7 treatment comparisons .
Anti-virals (2 comparisons)
Kinase inhibitor (3 comparisons)
Convalescent plasma (1 comparisons)
Others (1 comparisons)
General characteristics of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
new NCT04414124 Haran J, medRxiv, 2021 Full text Commentary thread Commentary |
Private | KB109 | Standard care | RCT | Outpatients with confirmed COVID-19 (mild) treated by 16 centers in the USA. | N=350 |
Some concerns Details |
|
new CTRI/2020/06/026087 Pandit A, Int J Infect Dis, 2021 Full text Commentary |
Private | Pegylated Interferon alpha-2b | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in India | N=40 |
Some concerns Details |
|
new IRCT20200310046736N1 Pouladzadeh M, Intern Emerg Med, 2021 Full text Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran | N=62 |
Some concerns Details |
|
new NCT04402866; EudraCT 2020-001807-18 Singh D, 2021 Full text Commentary Commentary |
Private | TD-0903 1 mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate) admitted to centers in Moldova, UK and Ukraine. | N=25 |
Some concerns Details |
|
| TD-0903 1 mg | TD-0903 3 mg | |||||||
| TD-0903 1 mg | TD-0903 10 mg | |||||||
| TD-0903 3 mg | Placebo | |||||||
| TD-0903 3 mg | TD-0903 10 mg | |||||||
| TD-0903 10 mg | Placebo | |||||||
new IRCT20200318046812N1 Solaymani-Dodaran M, Int Immunopharmacol, 2021 Full text Commentary |
Public/non profit | Favipiravir | Lopinavir-Ritonavir | RCT | Patients with suspected or confirmed COVID-19 (severe) admitted to 20 centers in Iran | N=424 |
Some concerns Details |
|